NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court

Novo Nordisk's experimental cardiovascular drug ziltivekimab failed a key late-stage trial.

The failure is a pipeline setback for Novo Nordisk.

The setback affects Novo Nordisk's efforts to diversify beyond obesity and diabetes treatments.

NVO stock ended a three-month winning streak following the news.

Competition in the market has also moved to court.